Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Biomarin Pharmaceutical Inc Stock Research

BMRN

88.06USD+1.02(+1.17%)Market Closed
Watchlist

Market Summary

USD88.06+1.02
Market Closed
1.17%

BMRN Alerts

  • Big jump in Earnings (Y/Y)

BMRN Stock Price

BMRN RSI Chart

BMRN Valuation

Market Cap

16.6B

Price/Earnings (Trailing)

165.7

Price/Sales (Trailing)

7.41

EV/EBITDA

82.27

Price/Free Cashflow

329.99

BMRN Price/Sales (Trailing)

BMRN Profitability

Operating Margin

77.30%

EBT Margin

3.32%

Return on Equity

1.54%

Return on Assets

1.11%

Free Cashflow Yield

0.3%

BMRN Fundamentals

BMRN Revenue

Revenue (TTM)

2.2B

Revenue Y/Y

11.52%

Revenue Q/Q

-0.19%

BMRN Earnings

Earnings (TTM)

100.0M

Earnings Y/Y

102.57%

Earnings Q/Q

10.2%

Price Action

52 Week Range

80.53117.77
(Low)(High)

Last 7 days

-0.9%

Last 30 days

-6.0%

Last 90 days

-4.5%

Trailing 12 Months

7.2%

BMRN Financial Health

Current Ratio

4.75

BMRN Investor Care

Shares Dilution (1Y)

1.56%

Diluted EPS (TTM)

0.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for BMRN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-16
Ajer Jeffrey Robert
sold
-450,000
90.00
-5,000
evp, chief commercial officer
2023-08-10
FUCHS HENRY J
sold
-1,085,110
90.4259
-12,000
president, worldwide r&d
2023-08-09
Guyer Charles Greg
sold
-500,109
93.304
-5,360
evp, chief technical officer
2023-08-08
BIENAIME JEAN JACQUES
sold
-529,740
88.29
-6,000
chief executive officer
2023-08-08
Davis George Eric
sold
-983,662
89.4238
-11,000
evp, chief legal officer
2023-08-07
BIENAIME JEAN JACQUES
sold
-352,400
88.1
-4,000
chief executive officer
2023-06-29
Mueller Brian
sold (taxes)
-869,735
88.93
-9,780
evp, chief financial officer
2023-05-23
Dere Willard H
acquired
-
-
4,190
-
2023-05-23
MEIER RICHARD A
acquired
-
-
4,190
-
2023-05-23
Slamon Dennis
acquired
-
-
4,190
-

1–10 of 50

Which funds bought or sold BMRN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Baystate Wealth Management LLC
reduced
-25.00
-12,892
26,004
-%
2023-09-21
Jefferies Group LLC
added
794
1,644,580
1,846,290
0.01%
2023-09-20
BARCLAYS PLC
added
65.83
74,627,000
230,678,000
0.15%
2023-09-18
WASHINGTON CAPITAL MANAGEMENT, INC
unchanged
-
-68,640
563,420
0.48%
2023-09-12
Farther Finance Advisors, LLC
added
309
2,831
3,901
-%
2023-08-29
EFG Asset Management (Americas) Corp.
new
-
1,439,060
1,439,060
0.33%
2023-08-28
DT Investment Partners, LLC
unchanged
-
-1,844
20,559
-%
2023-08-24
PERCEPTIVE ADVISORS LLC
reduced
-60.89
-42,633,600
22,814,800
0.66%
2023-08-24
Alberta Investment Management Corp
added
50.57
123,106
482,894
-%
2023-08-24
Arlington Capital Management, Inc.
sold off
-100
-2,801,480
-
-%

1–10 of 41

Latest Funds Activity

Are funds buying BMRN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BMRN
No. of Funds

Schedule 13G FIlings of Biomarin Pharmaceutical

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
dodge & cox
7.7%
14,383,663
SC 13G/A
Feb 13, 2023
capital research global investors
3.0%
5,651,001
SC 13G/A
Feb 09, 2023
primecap management co/ca/
9.46%
17,580,859
SC 13G/A
Feb 09, 2023
vanguard group inc
9.34%
17,365,080
SC 13G/A
Feb 03, 2023
blackrock inc.
8.2%
15,206,690
SC 13G/A
Mar 11, 2022
blackrock inc.
7.6%
14,021,292
SC 13G/A
Feb 14, 2022
dodge & cox
8.1%
14,825,049
SC 13G/A
Feb 10, 2022
primecap management co/ca/
9.7%
17,804,780
SC 13G/A
Feb 09, 2022
vanguard group inc
8.91%
16,351,031
SC 13G/A
Feb 08, 2022
blackrock inc.
7.6%
14,021,292
SC 13G

Recent SEC filings of Biomarin Pharmaceutical

View All Filings
Date Filed Form Type Document
Aug 17, 2023
4
Insider Trading
Aug 16, 2023
144
Notice of Insider Sale Intent
Aug 11, 2023
4
Insider Trading
Aug 10, 2023
4
Insider Trading
Aug 10, 2023
144
Notice of Insider Sale Intent
Aug 09, 2023
4
Insider Trading
Aug 09, 2023
4
Insider Trading
Aug 09, 2023
144
Notice of Insider Sale Intent
Aug 08, 2023
144
Notice of Insider Sale Intent
Aug 08, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Biomarin Pharmaceutical)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
143.9B
26.6B
4.94% 20.46%
18.04
5.41
0.75% 21.34%
94.2B
27.4B
-1.73% 23.33%
17.17
3.44
-0.48% 32.56%
37.4B
10.7B
-12.34% -18.02%
30.97
3.51
-53.67% -91.41%
37.3B
10.0B
-2.41% 31.83%
14.01
3.74
-6.23% 29.40%
MID-CAP
11.2B
1.7B
6.64% 14.01%
63.44
6.69
29.01% 1345.90%
4.3B
-
-10.44% 191.13%
-7.34
48.33
54.84% -12.96%
2.9B
-
-7.08% -17.64%
-22.89
37.44
122.90% 54.78%
1.8B
80.2M
1.68% -49.31%
-5.62
22.95
42.17% -39.82%
SMALL-CAP
1.4B
121.2M
-15.01% -21.70%
-4.98
11.8
-70.36% -531.73%
941.3M
15.3M
-22.34% -0.87%
-5.18
61.48
1090.59% -36.57%
670.5M
1.6B
-11.68% -62.32%
-1.14
0.42
23.74% 60.24%
199.0M
-
-23.19% -90.40%
-0.94
1.45
116.83% 16.61%
118.0M
-
-12.12% -85.84%
-0.59
0.49
113.96% -15.19%
107.9M
2.1M
-9.82% -66.03%
-1.07
52.51
487.70% -8.66%
3.7M
-
-11.16% -96.28%
-0.05
3.21
- -129.46%

Biomarin Pharmaceutical News

MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average ....
MarketBeat,
6 hours ago
London South East
StockNews.com
London South East
Investor's Business Daily

Returns for BMRN

Cumulative Returns on BMRN

1.7%


10-Year Cumulative Returns

-1.4%


7-Year Cumulative Returns

-2.1%


5-Year Cumulative Returns

4.4%


3-Year Cumulative Returns

Risks for BMRN

What is the probability of a big loss on BMRN?

65.4%


Probability that Biomarin Pharmaceutical stock will be more than 20% underwater in next one year

30%


Probability that Biomarin Pharmaceutical stock will be more than 30% underwater in next one year.

18.5%


Probability that Biomarin Pharmaceutical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BMRN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Biomarin Pharmaceutical was unfortunately bought at previous high price.

Drawdowns

Financials for Biomarin Pharmaceutical

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.8%2,2352,1732,0962,0081,9121,8801,8461,8491,9171,8441,8601,8631,8471,8051,7041,6031,5331,5191,4911,4961,439
Cost Of Revenue1.0%498493484476463467471477562533524494402382359339321322315316297
Costs and Expenses2.0%2,1432,1021,9461,9001,8541,8501,9291,9171,9871,9681,9041,8641,7881,7471,8051,7321,6831,6521,6151,5241,464
  S&GA Expenses2.1%901882854826792780759737733725738730721706681657636628604600582
  R&D Expenses2.9%680661650638638641629624614635628644670674715718706696696690682
EBITDA-100.0%-15726818814612748.0046.0036.0013.0092.0012319219234.00------
EBITDA Margin-100.0%-0.07*0.13*0.09*0.08*0.07*0.03*0.02*0.02*0.01*0.05*0.07*0.10*0.11*0.02*------
Interest Expenses-0.7%16.0016.0016.0016.0015.0015.0015.0016.0022.0026.0029.0031.0025.0024.0023.0024.0033.0039.0044.0048.0046.00
Earnings Before Taxes49.8%10872.0015010156.0036.00-75.35-55.64-70.69-127-49.00-11.9259.0059.00-94.81-128-157-144-142-44.80-46.00
EBT Margin-100.0%-0.03*0.07*0.05*0.03*0.02*-0.04*-0.03*-0.03*-0.07*-0.02*-0.01*0.03*0.03*-0.06*------
Net Income39.6%10072.0014284.0054.0039.00-64.0811.00832790854852122114-23.85-42.52-110-89.53-77.21-124-124
Net Income Margin-100.0%-0.03*0.07*0.04*0.03*0.02*-0.03*0.01*0.44*0.43*0.46*0.46*0.07*0.06*-0.01*------
Free Cashflow-100.0%-31.0055.0066.0016.0047.00209182173115-28.9522.00-10.34-68.89-96.76------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets2.0%6,5636,4346,3756,2646,1466,0636,0055,9775,8985,8055,8486,1585,3024,7234,6904,5584,3934,4354,4274,6954,625
  Current Assets3.8%2,9502,8422,7512,6832,5182,3942,2742,3122,3582,2892,3422,7392,6482,1161,9421,8591,8071,9172,0562,4082,280
    Cash Equivalents19.7%6945807257626206055876176426676491,016819477437423308364494882427
  Inventory6.2%976919894839802786777749711714699701744706680609579535531508473
  Net PPE-0.1%1,0671,0681,0731,0521,0491,0401,0351,0251,0271,0221,0321,0151,0111,0101,011969963952949924900
  Goodwill0%196196196196196196196196196196196196196196197197197197197197197
Liabilities0.3%1,7801,7751,7721,6961,6411,6711,7391,7111,6571,6431,7422,1042,0651,4831,5681,4841,4321,4991,4591,7801,740
  Current Liabilities-0.2%597598589521465490546515443430493855813820933494439501523839805
Shareholder's Equity2.7%4,7834,6594,6034,5694,5004,3864,2664,2614,2374,1624,1014,0543,2373,2403,1223,0742,9612,9372,9682,9152,885
  Retained Earnings7.6%-682-738-789-788-777-804-930-867-831-844-861-883-1,668-1,639-1,720-1,735-1,790-1,753-1,694-1,690-1,677
  Additional Paid-In Capital1.4%5,4945,4185,4055,3365,2735,2065,1925,1345,0845,0114,9934,9384,8864,8554,8334,7834,7444,6834,6704,6214,577
Accumulated Depreciation2.8%829807802782762741721--------------
Shares Outstanding0.3%188188186186185184184183183182182181181180180179179178178177177
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations9.4%16114717618011914630528026921485.0015614088.0048.0040.0017.008.0020.00-14.55-23.46
  Share Based Compensation1.5%205202196193188196197201202192190180169164160158156155149146145
Cashflow From Investing43.0%-78.59-137-20.03-20.74-117-207-366-299-73.32-201-53.62-113-17197.00-31.03-53.09301286264475-357
Cashflow From Financing69.6%-10.37-34.11-18.65-15.12-23.69-0.96-0.05-380-376176181551546-69.36-74.67-445-437-403-388-8.55468
  Buy Backs-----------50.00----------

BMRN Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
REVENUES:    
Total revenues$ 595,275$ 533,798$ 1,191,690$ 1,053,157
OPERATING EXPENSES:    
Cost of sales128,082123,126254,631240,091
Research and development177,363158,190349,209319,026
Selling, general and administrative215,336196,835438,339391,454
Intangible asset amortization and contingent consideration15,62416,49531,29434,107
Gain on sale of nonfinancial assets, net000(108,000)
Total operating expenses536,405494,6461,073,473876,678
INCOME FROM OPERATIONS58,87039,152118,217176,479
Interest income12,6122,50524,5554,325
Interest expense(3,755)(3,859)(7,458)(7,665)
Other income (expense), net3,083(2,947)(7,747)(4,101)
INCOME BEFORE INCOME TAXES70,81034,851127,567169,038
Provision for income taxes14,7707,18720,67520,576
NET INCOME$ 56,040$ 27,664$ 106,892$ 148,462
Earnings per share, basic (in dollars per share)$ 0.30$ 0.15$ 0.57$ 0.80
Earnings per share, diluted (in dollars per share)$ 0.29$ 0.15$ 0.56$ 0.79
Weighted average common shares outstanding, basic (in shares)187,948185,254187,311184,710
Weighted average common shares outstanding, diluted (in shares)194,998187,448194,756191,096
COMPREHENSIVE INCOME$ 48,145$ 47,013$ 92,142$ 152,502
Net product revenues    
REVENUES:    
Total revenues584,698517,6601,171,1241,023,185
Royalty and other revenues    
REVENUES:    
Total revenues$ 10,577$ 16,138$ 20,566$ 29,972

BMRN Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
[1]
Current assets:  
Cash and cash equivalents$ 694,381$ 724,531
Short-term investments476,577567,006
Accounts receivable, net610,222461,316
Inventory975,546894,083
Other current assets193,391104,521
Total current assets2,950,1172,751,457
Noncurrent assets:  
Long-term investments385,777333,835
Property, plant and equipment, net1,067,2781,073,366
Intangible assets, net310,343338,569
Goodwill196,199196,199
Deferred tax assets1,509,2901,505,412
Other assets144,168176,236
Total assets6,563,1726,375,074
Current liabilities:  
Accounts payable and accrued liabilities597,231572,959
Short-term contingent consideration015,925
Total current liabilities597,231588,884
Noncurrent liabilities:  
Long-term convertible debt, net1,084,9941,083,019
Other long-term liabilities98,120100,015
Total liabilities1,780,3451,771,918
Stockholders’ equity:  
Common stock, $0.001 par value: 500,000,000 shares authorized; 188,151,695 and 186,250,719 shares issued and outstanding, respectively188186
Additional paid-in capital5,493,9565,404,895
Company common stock held by the Nonqualified Deferred Compensation Plan(10,393)(8,859)
Accumulated other comprehensive loss(18,617)(3,867)
Accumulated deficit(682,307)(789,199)
Total stockholders’ equity4,782,8274,603,156[2]
Total liabilities and stockholders’ equity$ 6,563,172$ 6,375,074
[1](1)December 31, 2022 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 27, 2023.
[2]The beginning balances for the six-month periods were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 27, 2023.
Jean-Jacques Bienaimé
3040
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.